Ni X, Lu C, Xu G, Ma J
Acta Pharmacol Sin. 2024; 45(8):1533-1555.
PMID: 38622288
PMC: 11272797.
DOI: 10.1038/s41401-024-01264-1.
Azevedo-Silva J, Tavares-Valente D, Almeida A, Queiros O, Baltazar F, Ko Y
Med Oncol. 2022; 39(9):121.
PMID: 35716210
DOI: 10.1007/s12032-022-01712-0.
Petricciuolo M, Davidescu M, Fettucciari K, Gatticchi L, Brancorsini S, Roberti R
Heliyon. 2020; 6(12):e05741.
PMID: 33364504
PMC: 7753915.
DOI: 10.1016/j.heliyon.2020.e05741.
Gan L, Ren Y, Lu J, Ma J, Shen X, Zhuang Z
Onco Targets Ther. 2020; 13:11125-11137.
PMID: 33149623
PMC: 7605667.
DOI: 10.2147/OTT.S273108.
Liu J, Wang W, Wang L, Qi X, Sha Y, Yang T
Chin Med J (Engl). 2020; 133(1):49-60.
PMID: 31923104
PMC: 7028200.
DOI: 10.1097/CM9.0000000000000577.
Glycolytic suppression dramatically changes the intracellular metabolic profile of multiple cancer cell lines in a mitochondrial metabolism-dependent manner.
Shiratori R, Furuichi K, Yamaguchi M, Miyazaki N, Aoki H, Chibana H
Sci Rep. 2019; 9(1):18699.
PMID: 31822748
PMC: 6904735.
DOI: 10.1038/s41598-019-55296-3.
Diverse Stakeholders of Tumor Metabolism: An Appraisal of the Emerging Approach of Multifaceted Metabolic Targeting by 3-Bromopyruvate.
Yadav S, Pandey S, Goel Y, Temre M, Singh S
Front Pharmacol. 2019; 10:728.
PMID: 31333455
PMC: 6620530.
DOI: 10.3389/fphar.2019.00728.
Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma.
Yoo J, Yu S, Na J, Kim K, Cho Y, Lee Y
Int J Mol Sci. 2019; 20(6).
PMID: 30875800
PMC: 6471302.
DOI: 10.3390/ijms20061292.
Carbonic anhydrase-IX inhibition enhances the efficacy of hexokinase II inhibitor for hepatocellular carcinoma in a murine model.
Cho E, Yu S, Kim K, Cho H, Cho Y, Lee Y
J Bioenerg Biomembr. 2019; 51(2):121-129.
PMID: 30746618
DOI: 10.1007/s10863-019-09788-6.
Diverse Functions of Autophagy in Liver Physiology and Liver Diseases.
Ke P
Int J Mol Sci. 2019; 20(2).
PMID: 30642133
PMC: 6358975.
DOI: 10.3390/ijms20020300.
Taming Tumor Glycolysis and Potential Implications for Immunotherapy.
Ganapathy-Kanniappan S
Front Oncol. 2017; 7:36.
PMID: 28348977
PMC: 5346534.
DOI: 10.3389/fonc.2017.00036.
The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside.
Azevedo-Silva J, Queiros O, Baltazar F, Ulaszewski S, Goffeau A, Ko Y
J Bioenerg Biomembr. 2016; 48(4):349-62.
PMID: 27457582
DOI: 10.1007/s10863-016-9670-z.
Targeting glucose metabolism in cancer: new class of agents for loco-regional and systemic therapy of liver cancer and beyond?.
Savic L, Chapiro J, Duwe G, Geschwind J
Hepat Oncol. 2016; 3(1):19-28.
PMID: 26989470
PMC: 4792180.
DOI: 10.2217/hep.15.36.
Overexpression of ErbB2 renders breast cancer cells susceptible to 3-BrPA through the increased dissociation of hexokinase II from mitochondrial outer membrane.
Gao S, Chen X, Jin H, Ren S, Liu Z, Fang X
Oncol Lett. 2016; 11(2):1567-1573.
PMID: 26893781
PMC: 4734279.
DOI: 10.3892/ol.2015.4043.
Targeting glycolysis by 3-bromopyruvate improves tamoxifen cytotoxicity of breast cancer cell lines.
Attia Y, El-Abhar H, Al Marzabani M, Shouman S
BMC Cancer. 2015; 15:838.
PMID: 26526196
PMC: 4630933.
DOI: 10.1186/s12885-015-1850-4.
Deregulation of energy metabolism promotes antifibrotic effects in human hepatic stellate cells and prevents liver fibrosis in a mouse model.
Karthikeyan S, Potter J, Geschwind J, Sur S, Hamilton J, Vogelstein B
Biochem Biophys Res Commun. 2015; 469(3):463-9.
PMID: 26525850
PMC: 5548097.
DOI: 10.1016/j.bbrc.2015.10.101.
3-BrPA eliminates human bladder cancer cells with highly oncogenic signatures via engagement of specific death programs and perturbation of multiple signaling and metabolic determinants.
Konstantakou E, Voutsinas G, Velentzas A, Basogianni A, Paronis E, Balafas E
Mol Cancer. 2015; 14:135.
PMID: 26198749
PMC: 4511243.
DOI: 10.1186/s12943-015-0399-9.
Effect of 3-bromopyruvate and atovaquone on infection during in vitro interaction of Toxoplasma gondii and LLC-MK2 cells.
de Lima L, Seabra S, Carneiro H, Barbosa H
Antimicrob Agents Chemother. 2015; 59(9):5239-49.
PMID: 26077255
PMC: 4538506.
DOI: 10.1128/AAC.00337-15.
Metabolic perturbation sensitizes human breast cancer to NK cell-mediated cytotoxicity by increasing the expression of MHC class I chain-related A/B.
Fu D, Geschwind J, Karthikeyan S, Miller E, Kunjithapatham R, Wang Z
Oncoimmunology. 2015; 4(3):e991228.
PMID: 25949910
PMC: 4404839.
DOI: 10.4161/2162402X.2014.991228.
Occurrence of a multimeric high-molecular-weight glyceraldehyde-3-phosphate dehydrogenase in human serum.
Kunjithapatham R, Geschwind J, DeVine L, Boronina T, OMeally R, Cole R
J Proteome Res. 2015; 14(4):1645-56.
PMID: 25734908
PMC: 4841454.
DOI: 10.1021/acs.jproteome.5b00089.